California Public Employees Retirement System Has $10.22 Million Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

California Public Employees Retirement System cut its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 6.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 213,687 shares of the biopharmaceutical company's stock after selling 15,172 shares during the quarter. California Public Employees Retirement System owned about 0.17% of Halozyme Therapeutics worth $10,216,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the company. Venturi Wealth Management LLC bought a new position in shares of Halozyme Therapeutics in the 4th quarter valued at about $69,000. Retirement Systems of Alabama lifted its stake in Halozyme Therapeutics by 23.5% in the 3rd quarter. Retirement Systems of Alabama now owns 389,268 shares of the biopharmaceutical company's stock valued at $22,282,000 after purchasing an additional 74,173 shares during the last quarter. Shaker Investments LLC OH lifted its stake in Halozyme Therapeutics by 12.3% in the 4th quarter. Shaker Investments LLC OH now owns 75,326 shares of the biopharmaceutical company's stock valued at $3,601,000 after purchasing an additional 8,249 shares during the last quarter. Foster & Motley Inc. increased its position in Halozyme Therapeutics by 118.6% during the fourth quarter. Foster & Motley Inc. now owns 23,280 shares of the biopharmaceutical company's stock worth $1,113,000 after buying an additional 12,630 shares during the last quarter. Finally, Jennison Associates LLC acquired a new position in Halozyme Therapeutics during the fourth quarter worth approximately $731,000. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Halozyme Therapeutics Stock Performance

Shares of HALO stock traded up $2.52 on Friday, hitting $60.22. The company's stock had a trading volume of 1,839,648 shares, compared to its average volume of 1,409,402. Halozyme Therapeutics, Inc. has a fifty-two week low of $37.73 and a fifty-two week high of $66.00. The company has a market capitalization of $7.44 billion, a PE ratio of 17.56, a PEG ratio of 0.42 and a beta of 1.32. The stock's 50 day moving average is $60.15 and its 200-day moving average is $54.90. The company has a debt-to-equity ratio of 4.14, a quick ratio of 9.15 and a current ratio of 7.80.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its quarterly earnings data on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.17 by $0.02. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. The firm had revenue of $298.01 million during the quarter, compared to the consensus estimate of $285.74 million. Equities research analysts expect that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Insider Activity at Halozyme Therapeutics

In related news, Director Jeffrey William Henderson sold 5,000 shares of the company's stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $56.30, for a total transaction of $281,500.00. Following the completion of the sale, the director now owns 38,611 shares of the company's stock, valued at $2,173,799.30. This represents a 11.46 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, SVP Michael J. Labarre sold 1,697 shares of the stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $58.28, for a total transaction of $98,901.16. Following the sale, the senior vice president now owns 173,756 shares in the company, valued at $10,126,499.68. The trade was a 0.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 22,200 shares of company stock worth $1,286,568. Company insiders own 2.40% of the company's stock.

Analyst Ratings Changes

Several brokerages have recently commented on HALO. Piper Sandler lifted their target price on Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a "neutral" rating in a research note on Friday, January 10th. Benchmark reaffirmed a "buy" rating and set a $75.00 price target on shares of Halozyme Therapeutics in a report on Thursday, February 20th. Wells Fargo & Company decreased their price objective on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating on the stock in a report on Monday, January 13th. Finally, HC Wainwright restated a "buy" rating on shares of Halozyme Therapeutics in a research note on Thursday, March 6th. Four research analysts have rated the stock with a hold rating and six have given a buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $62.78.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.